참고문헌
- Bewick V, Cheek L, Ball J (2004). Statistics review 13: receiver operating characteristic curves. Crit Care, 8, 508-12. https://doi.org/10.1186/cc3000
- Buergy D, Wenz F, Groden C, Brockmann MA (2012). Tumorplatelet interaction in solid tumors. Int J Cancer, 130, 2747-60. https://doi.org/10.1002/ijc.27441
- Burstein HJ (2005). The distinctive nature of HER2-positive breast cancers. N Engl J Med, 353, 1652-4. https://doi.org/10.1056/NEJMp058197
- Chen Y, Zhang L, Liu WX, Liu XY. (2015). Prognostic signifiance of preoperative anemia, leukocytosis and thrombocytosis in Chinese women with epithelial ovarian cancer. Asian Pac J Cancer Prev, 16, 933-9. https://doi.org/10.7314/APJCP.2015.16.3.933
- Early Breast Cancer Trialists' Collaborative Group (EBCTCG), C Davies, J Godwin, R Gray, et al (2011). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet, 378, 771-84. https://doi.org/10.1016/S0140-6736(11)60993-8
- Eltabbakh GH, Piver MS, Hempling RE, Recio FO, Intengen ME (1999). Clinical picture, response to therapy, and survival of women with diffuse malignant peritoneal mesothelioma. J Surg Oncol, 70, 6-12. https://doi.org/10.1002/(SICI)1096-9098(199901)70:1<6::AID-JSO2>3.0.CO;2-X
- Fang-Xuan Li, Li-Juan Wei, Huan Zhang, Shi-Xia Li, Jun-Tian Liu (2014). Significance of thrombocytosis in clinicopathologic characteristics and prognosis of gastric cancer. Asian Pac J Cancer Prev, 15, 6511-7. https://doi.org/10.7314/APJCP.2014.15.16.6511
- Foy KC, Miller MJ, Moldovan N (2012). Immunotherapy with HER-2 and VEGF peptide mimics plus metronomic paclitaxel causes superior antineoplastic effects in transplantable and transgenic mouse models of human breast cancer. Oncoimmunology, 1, 1004-16. https://doi.org/10.4161/onci.21057
- Gastl G, Plante M, Finstad CL, et al (1993). High IL-6 levels in ascitic fluid correlate with reactive thrombocytosis in patients with epithelial ovarian cancer. Br J Haematol, 83, 433-41. https://doi.org/10.1111/j.1365-2141.1993.tb04668.x
- Gerdes J, Schwab U, Lemke H, Stein H (1983). Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer, 31, 13-20. https://doi.org/10.1002/ijc.2910310104
- Gown AM (2008). Current issues in ER and HER-2 testing by IHC in breast cancer. Mod Pathol, 21, 8-15. https://doi.org/10.1038/modpathol.2008.34
- Ikeda M, Furukawa H, Imamura H, et al (2002). Poor prognosis associated with thrombocytosis in patients with gastric cancer. Ann Surg Oncol, 9, 287-91. https://doi.org/10.1007/BF02573067
- International Breast Cancer Study Group. Colleoni M, Gelber S, Goldhirsch A, et al (2006). Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph nodepositive breast cancer: international breast cancer study group trial 13-93. J Clin Oncol, 24, 1332-41. https://doi.org/10.1200/JCO.2005.03.0783
- Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL (2001). HER2 (neu) signaling increases the rate ofhypoxia-inducible factor 1 (HIF-1) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol, 21, 3995-4004. https://doi.org/10.1128/MCB.21.12.3995-4004.2001
- Li Y, Miao LY, Xiao YL, Cai HR, Zhang DP (2014). Elevated platelets enhance cancer cell migration,promote hematogenous metastasis and associate with a poor prognosis in advanced non-small cell lung cancer cases. Asian Pac J Cancer Prev, 15, 139-43. https://doi.org/10.7314/APJCP.2014.15.1.139
- Monreal M, Fernandez-Llamazares J, Pinol M, et al (1998). Platelet count and survival in patients with colorectal cancer-a preliminary study. Thromb Haemost, 79, 916-8.
- Nakano T, Chahinian AP, Shinjo M, et al (1998). Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma. Br J Cancer, 77, 907-12. https://doi.org/10.1038/bjc.1998.150
- O'Byrne KJ, Dobbs N, Propper D, Smith K, Harris AL (1999). Vascular endothelial growth factor platelet counts, and prognosis in renal cancer. Lancet, 353, 1494-5.
- O'Byrne KJ, Dobbs N, Propper D, Smith K, Harris AL (1999). Vascular endothelial growth factor platelet counts, and prognosis in renal cancer. Lancet, 353, 1494-5.
- Olesen LL, Thorshauge H (1988). Thrombocytosis in patients with malignant pleural mesothelioma. Cancer, 62, 1194-6. https://doi.org/10.1002/1097-0142(19880915)62:6<1194::AID-CNCR2820620625>3.0.CO;2-M
- Pathmanathan N, Balleine RL, Jayasinghe UW, et al (2014). The prognostic value ofKi67 in systemically untreated patients with node-negative breast cancer. J Clin Pathol, 67, 222-8. https://doi.org/10.1136/jclinpath-2013-201793
- Pedersen LM, Milman N (1996). Prognostic significance of thrombocytosis in patients with primary lung cancer. Eur Respir J, 9, 1826-30. https://doi.org/10.1183/09031936.96.09091826
- Puhalla S, Brufsky A (2013). Treatment of HER2-positive breast cancer:looking backwards briefly. Lancet Oncol, 14, 1250-1. https://doi.org/10.1016/S1470-2045(13)70536-9
- Ramirez A, Boulaiz H, Morata-Tarifa C, et al (2014). HER2-signaling pathway, JNK and ERKs kinases, and cancer stemlike cells are targets of Bozepinib. Onco Target, 5, 3590-606.
- Stravodimou A,Voutsadakis IA (2013). Pretreatment Thrombocytosis As A Prognostic Factor In Metastatic Breast Cancer. Int J Breast Cancer, 2013, 289563-8.
- Taucher S, Salat A, Gnant M, et al (2003). Impact of pretreatment thrombocytosis on survival in primary breast cancer. Thromb Haemost, 89, 1098-106.
- Verheul HM, Hoekman K, Luykx-de Bakker S, et al (1997). Platelet:transporter ofvascular endothelial growth factor. Clin Cancer Res, 3, 2187-90.
피인용 문헌
- Safety and Efficacy of Trastuzumab Emtansine in Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: a Meta-analysis vol.6, pp.1, 2016, https://doi.org/10.1038/srep23262
- The pretreatment thrombocytosis may predict prognosis of patients with colorectal cancer: a systematic review and meta-analysis vol.11, pp.2, 2017, https://doi.org/10.2217/bmm-2016-0214
- Motivation for Launching a Cancer Metastasis Inhibition (CMI) Program vol.13, pp.1, 2018, https://doi.org/10.1007/s11523-017-0542-1